In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

diaDexus, Inc.

http://www.diadexus.com/

Latest From diaDexus, Inc.

Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost

Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.

Financing Business Strategies

FTC Narrowly Okays AbbVie/Allergan Merger As Dissenter Slams Divestitures To AstraZeneca, Nestlé

Commissioner Chopra says candy maker Nestlé cannot take Allergans place in the market and AstraZeneca would get a windfall without paying anything for a valuable drug development project. AbbVie/Allergan must divest enzyme replacement therapies Zenpap and Viokace to Nestlé and investigational IL-23 inhibitor brazikumab to AstraZeneca. 

M & A Enforcement

More German Companies Get To Work On COVID-19 Diagnostic Test Development

Another three in vitro diagnostics companies in Germany are working on tests for the early detection of COVID-19, with confirmed infections reaching 89,000 globally by 2 March.

Germany Policy

Buying Encycle Gives Zealand Its First External Asset

Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.

Deals Gastrointestinal
See All

Company Information

  • Other Names / Subsidiaries
    • VaxGen, Inc.
UsernamePublicRestriction

Register